NYR 0.92% 5.5¢ nyrada inc.

Ann: Significant Neuroprotection in NYR Preclinical Brain Injury, page-186

  1. 10,189 Posts.
    lightbulb Created with Sketch. 1986
    It’s funny that they are fully funded all the way into phase 2 with non dilutive funding extending the companies funds well into phase 2 and the market cap is now trading below it’s coming up cash funding pricing nothing in for how de risked the drug is heading into phase 1 and phase 2 FDA approval. AGN is looking like on any good news will become a 200-300 million dollar company on the potential of the drug.
 
watchlist Created with Sketch. Add NYR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.